检索结果-南通市图书馆

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

引用

Asian Pacific Journal of Tropical Medicine 2021年第6期14卷 266-273页

作者： Morteza Shakhsi Niaee Peyman Namdar Abbas Allami Leila Zolghadr Amir Javadi Amin Karampour Mehran Varnaseri Behzad Bijani Fatemeh Cheraghi Yazdan Naderi Fatemeh Amini Masoumeh Karamyan Mohammad Jafar YadYad Ramin Jamshidian Nematollah Gheibi Sciences and Technology Park QazvinIran Department of Surgery Qazvin University of Medical SciencesQazvinIran Department of Infectious Diseases Clinical Research Development UnitBouAliSina HospitalQazvin University of Medical SciencesQazvinIran Department of Chemistry Imam Khomeini International University QazvinIran Department of Social Sciences School of Medicine Qazvin University of Medical SciencesQazvinIran Infectious and Tropical Diseases Research Center Ahvaz Jundishapur University of Medical SciencesAhvazIran Department of Infectious Diseases Qazvin University of Medical SciencesQazvinIran Cellular and Molecular Research Center Research Institute for Prevention of Non-Communicable DiseasesQazvin University of Medical SciencesQazvinIran Department of Persian Medicine School of MedicineShiraz University of Medical SciencesShirazIran

Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical ***: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed at five hospitals. A total of 180 mild hospitalized patients with COVID-19 confirmed by PCR or chest image tests were enrolled and allocated to six arms including hydroxychloroquine 200 mg twice per day, placebo plus hydroxychloroquine 200 mg twice per day, single dose ivermectin(200 μg/kg), three low interval doses of ivermectin(200, 200, 200 μg/kg), single dose ivermectin(400 μg/kg), and three high interval doses of ivermectin(400, 200, 200 μg/kg). The primary endpoint of this trial was all-cause of mortality or clinical recovery. The radiographic findings, hospitalization and low O_2 saturation duration, and hematological variables of blood samples were analyzed. Results: A total of 16.7%(5/30) and 20.0%(6/30) patients died in arms treated with hydroxychloroquine 200 mg twice per day and placebo plus hydroxychloroquine 200 mg twice per day, respectively, and a reduction in mortality rate in patients receiving ivermectin treatment to 0%, 10%, 0% and 3.3% for arms 1-4 were observed. Risk of mortality was also decreased about 15% in the ivermectin treated arms. Conclusions: Ivermectin as an adjunct reduces the rate of mortality, time of low O_2 saturation, and duration of hospitalization in adult COVID-19 patients. The improvement of other clinical parametersshows that ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19.

关键词： SARS-COV-2 Ivermectin Randomized controlled trial dose-respond relationship

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：